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Tat Competes with CIITA for the Binding to P-TEFb
and Blocks the Expression
of MHC Class II Genes in HIV Infection
groups of BLS have been described. The first four repre-
sent mutations in three members of the regulatory factor
X (RFX) complex and the class II transactivator (CIITA)
(reviewed by Mach et al., 1996, and Masternak et al.,
1998; Nagarajan et al., 1999). The last complementation
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²Department of Molecular Genetics II heterodimers cannot form (Douhan et al., 1996). CIITA
neither binds to DNA nor appears in electrophoreticNagoya City University Medical School
Nagoya 467 mobility shift assays on MHC II promoters (Steimle et
al., 1993). However, it requires the occupancy of MHCJapan
II promoters to function (reviewed by Mach et al., 1996)
and interacts weakly with the RFX complex (Scholl et al.,
1997). CIITA then binds to general transcription factorsSummary
(GTFs) (Fontes et al., 1997; Mahanta et al., 1997), the B
cell octamer binding protein 1 (Bob1) (Fontes et al.,AIDS and the bare lymphocyte syndrome (BLS) are
1996), and the histone acetyltransferase CREBP-bindingsevere combined immunodeficiencies. BLS results
protein (CBP) (Kretsovali et al., 1998; Fontes et al., 1999)from mutations in genes that regulate the expression
to initiate the transcription of MHC II genes. It can beof class II major histocompatibility (MHC II) determi-
considered a master switch of genes that regulate anti-nants. One of these is the class II transactivator (CIITA).
gen processing and presentation (reviewed by Mach etHIV and its transcriptional transactivator (Tat) also
al., 1996). Not only does the introduction of CIITA intoblock the expression of MHC II genes. By binding to
somatic cells result in the transcription of MHC II, thethe same surface in the cyclin T1, which together with
invariant chain (Ii), and monomorphic DMA and DMBCDK9 forms the positive transcription elongation fac-
genes, but its absence also correlates with the extinctiontor b (P-TEFb) complex, Tat inhibits CIITA. CIITA can
of MHC II determinants on plasma cells (reviewed byalso activate transcription when tethered artificially to
Mach et al., 1996). Finally, the induction of MHC II tran-RNA. Moreover, a dominant-negative CDK9 protein
scription by interferon-g (IFNg) is mediated by CIITAinhibits the activity of MHC II promoters. Thus, CIITA
(Chang et al., 1994; Steimle et al., 1994).is a novel cellular coactivator that binds to P-TEFb for
HIV-1 encodes a potent transcriptional transactivatorthe expression of its target genes.
(Tat) that binds to an RNA stem loop called the transacti-
vation response (TAR) element (reviewed by Jones and
Peterlin, 1994). Interactions between Tat and TAR in-Introduction
crease rates of elongation rather than initiation of viral
transcription. Recently, the coactivator for Tat has beenThe human immunodeficiency virus (HIV-1) causes the
acquired immunodeficiency syndrome (AIDS) (Barre- identified (Wei et al., 1998). The cyclin T1, which together
with CDK9 forms the positive transcription elongationSinoussi et al., 1983). It infects macrophages and T cells
bearing CD4 and appropriate chemokine receptors, factor b (P-TEFb) complex (Peng et al., 1998), binds to
the activation domain of Tat (Wei et al., 1998). Tat, cyclinCCR5 and CXCR4, respectively (reviewed by Locati and
Murphy, 1999). Infection of macrophages by HIV-1 has T1, and TAR then form a high affinity RNA±protein com-
plex that phosphorylates the C-terminal domain (CTD)been correlated with their progressive functional impair-
ments, which include defects in chemotaxis, cytokine of RNA polymerase II (RNAPII) (Bieniasz et al., 1998;
Garber et al., 1998; Chen et al., 1999; Fujinaga et al.,production, expression of surface proteins, and antigen
processing and presentation (reviewed by Knight et al., 1999; Ivanov et al., 1999). The conversion of an unphos-
1990 and Petit et al., 1988; Ennen et al., 1990; Roilides phorylated to a phosphorylated RNAPII (RNAPIIa to
et al., 1990; Macatonia et al., 1992; Polyak et al., 1997). RNAPIIo) marks the transitions from initiation to elonga-
Significantly, HIV-1 has been reported to block the tran- tion of transcription (reviewed by Shilatifard, 1998).
scription of class II major histocompatibility (MHC II) In this report, we investigated whether Tat was re-
determinants as well as antigen processing and presen- sponsible for blocking the transcription of MHC II genes
tation in primary macrophages and macrophage hybrid- in cells that are infected by HIV-1. Indeed, HIV-1 and
omas (Polyak et al., 1997). These effects may contribute Tat blocked the expression of MHC II determinants on
significantly to the immunopathology of AIDS. macrophages and B cells, respectively, and inhibited the
The bare lymphocyte syndrome (BLS) is a congenital ability of CIITA to activate MHC II promoters. Moreover,
immunodeficiency which results from mutations in CIITA bound to the same surface on the cyclin T1 as
genes that regulate the transcription of MHC II genes Tat, and Tat blocked the binding of CIITA to the cyclin
(reviewed by Mach et al., 1996). Five complementation T1. N-terminal sequences in CIITA that bound to the
cyclin T1 also could activate transcription via RNA. We
conclude that CIITA requires P-TEFb to activate the³ To whom correspondence should be addressed (e-mail: matija@
itsa.ucsf.edu). transcription of MHC II genes. The inhibition of CIITA
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Figure 1. HIV-1 and Tat Block the Expression of MHC II Determi-
nants
(A) HIV-1YU2 infection decreases the expression of MHC II determi-
nants on THP-1 cells. THP-1 cells were infected with the macro-
phage-tropic HIV-1YU2 and monitored for 8 days. On day 9, cells were
incubated with anti-MHC I (HLA-A, -B, and -C) and MHC II (HLA-
DR) antibodies and examined by FACS. The left-hand panel contains
cells stained with the anti-MHC I antibody (MHC I). The right-hand
panel contains cells stained with the anti-MHC II antibody (MHC II).
Relative fluorescence intensities are as follows: white areas under
solid lines, uninfected THP-1 cells; gray areas under solid lines,
infected THP-1 cells; white area under the dashed line, unstained
cells. Unstained cells are presented only in the right-hand panel
Figure 2. Tat Blocks the Activation of the DRA Promoter by CIITA
(MHC II).
and the Presentation of Superantigen by B Cells to T Cells
(B) Tat blocks the induction of MHC II determinants by IFNg in HeLa
(A) Tat blocks the activation of the DRA promoter by CIITA in cells.cells. HeLa cells expressing Tat or the empty plasmid vector were
The DRA promoter linked to the CAT reporter gene was coexpressedincubated with IFNg for 3 days. On day 4, cells were stained with
with CIITA and increasing amounts of Tat and mutant TatC30Ganti-MHC I (HLA-A, -B, and -C) and MHC II (HLA-DP) antibodies and
proteins in COS cells. Amounts of cotransfected plasmids are pre-examined by FACS. Right- and left-hand panels are as above (MHC
sented above the bar graph. Amounts of expressed proteins, whichI and MHC II). Relative fluorescence intensities are as follows: white
were assessed by Western blotting, are given below the bar graph.areas under bold lines, HeLa cells, which expressed the empty
Experiments are representative of three independent transfections,plasmid vector, treated with IFNg; gray areas under solid lines, HeLa
which were performed in duplicate. Error bars give standard errorscells, which expressed Tat (HeLa.Tat), treated with IFNg; white areas
of the mean.under solid lines, HeLa cells, which were not treated with IFNg;
(B) Tat blocks the presentation of superantigen by B cells to T cells.white area under the dashed line, unstained HeLa cells. Unstained
RM3 cells coexpressed CIITA and Tat at a ratio of 1:3 for 3 days.HeLa cells are presented only in the right-hand panel (MHC II).
On day 4, they were incubated with SED and combined with Jurkat
cells, which contained the NFAT-luciferase plasmid reporter. Lucif-
erase activity was determined 16 hr later. The diagram on the leftby Tat might also contribute significantly to the immuno-
describes the superantigen assay. Levels of HLA-DR and DP onpathology of AIDS.
RM3 cells that coexpressed CIITA and Tat are presented above the
bar graph, with those of RM3 cells that expressed only CIITA set
Results to 100. Coexpressed proteins are indicated below the bar graph.
White and black bars represent experiment without SED and with
SED, respectively. Experiments are representative of three indepen-Infection by HIV-1 and the Introduction of Tat Block
dent transfections, which were performed in duplicate. Error barsthe Expression of MHC II Determinants
give standard errors of the mean.To confirm the previous report that HIV-1 blocks the
expression of MHC II determinants, human monocytoid
cells (THP-1 cells) (Auwerx, 1991) were infected with the To determine if Tat was responsible for this inhibition,
we studied the induction of MHC II determinants by IFNgmacrophage-tropic HIV-1YU2 (Li et al., 1991). The expres-
sion of MHC II determinants is constitutive on these in HeLa cells that expressed wild-type and mutant Tat
proteins. The incubation of HeLa cells with IFNg resultscells (Figure 1A) (Auwerx, 1991). Eight days after the
infection, levels of class I major histocompatibility (MHC in de novo synthesis of MHC II transcripts, which re-
quires CIITA (Chang et al., 1994; Steimle et al., 1994).I) and MHC II determinants were determined by fluores-
cence activated cell sorting (FACS) analyses (Figure 1A). The binding of IFNg to its receptor activates Janus ki-
nases and the translocation of the signal transducer andHIV-1YU2 reduced levels of MHC I and MHC II 2- and 20-
fold, respectively (Figure 1A, compare panels on the left activator of transcription 1 (STAT1) to the nucleus, which
leads to the transcription of CIITA from its IFNg-induc-and right). Similar to Polyak et al. (1997), reduced levels
correlated with the absence of MHC II RNA in infected ible promoter (Muhlethaler-Mottet et al., 1997, 1998;
Piskurich et al., 1999). CIITA then interacts with MHC IIcells (data not shown). Thus, HIV-1 blocks the expres-
sion of MHC II genes. promoters to activate their transcription (Chang et al.,
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Figure 3. The Cyclin Box in the Cyclin T1 Binds to N-Terminal Sequences in CIITA In Vitro
(A) CIITA binds to the cyclin box in the cyclin T1. Hybrid GST-cyclin T1 proteins were expressed in E. coli and purified by affinity chromatography.
CIITA was transcribed and translated in vitro using the rabbit reticulocyte lysate. Presented above the pull downs is a diagrammatic representa-
tion of the cyclin T1, deletion mutants of the cyclin T1, and proteins used in binding studies. In the cyclin T1, N-terminal 250 residues contain
two repeated cyclin boxes, followed by TRM and C-terminal PEST motifs. The arrow points to the CIITA band in the autoradiograph. The first
eight lanes represent pull downs, and lane 9 shows 25% of the input CIITA. In the lower panel are presented GST and GST fusion proteins
(GST-chimeras) used in the binding reactions. They were visualized by Coomassie staining of the SDS-polyacrylamide gel.
(B) Cyclin T1 binds to N-terminal sequences in CIITA. Interacting proteins were isolated and visualized as in (A). Presented above the pull
down is a diagrammatic representation of CIITA, deletion mutants of CIITA, and proteins used in binding studies. The activation domain in
CIITA (AD) is followed by the proline/serine/threonine-rich (P/S/T) region, a putative GTP-binding site (GTP), and the C-terminal nuclear
localization signal (NLS). Twenty-five percent of input proteins (CIITA and mutant CIITA proteins) are given in the lower autoradiograph.
1994; Steimle et al., 1994). Inducible cells were chosen plasmid targets containing the HLA-DRA promoter
linked to the chloramphenicol acetyltransferase (CAT)because of the slow decay of MHC II determinants on
antigen-presenting cells (APC) (Lanzavecchia et al., reporter gene (Figure 2A). As observed previously, CIITA
activated the transcription from this promoter in COS1992; Nelson et al., 1994). As presented in Figure 1B, the
administration of IFNg led to a 10-fold higher induction of cells (Figure 2A, lane 2) (Fontes et al., 1999). The coex-
pression of Tat reduced levels of CAT enzymatic activityMHC II determinants on HeLa cells that expressed the
empty plasmid vector than those that expressed Tat from the DRA promoter up to 7-fold (Figure 2A, compare
lanes 3, 4, and 5 with lane 2). In sharp contrast, the(HeLa.Tat) (Figure 1B, panel on right, compare white and
gray peaks). Cells that expressed the mutant TatC30G mutant TatC30G protein, which no longer binds to the
cyclin T1 (Fujinaga et al., 1999), had almost no effectprotein, which is inactive for Tat transactivation, were
indistinguishable from parental HeLa cells (data not (Figure 2A, lanes 6±8). Importantly, Tat did not decrease
levels of expression of CIITA from the cotransfectedshown). Despite the presence of sequences encoded
by both exons from the tat gene, no effect of Tat was plasmid (Figure 2A, upper Western blot), and Tat had
no effect on the DRA promoter in the absence of CIITAobserved on levels of MHC I determinants on these cells
(Figure 1B, panel on left). We conclude that HIV-1 blocks (data not shown). Amounts of the Tat protein also corre-
lated with this inhibition (Figure 2A, lower Western blot).the expression of MHC II determinants and that Tat is
primarily responsible for this effect. We conclude that Tat blocks the ability of CIITA to acti-
vate MHC II promoters and that the activation domain
of Tat is responsible for this effectTat Blocks the Ability of CIITA to Activate
MHC II Promoters
Our results suggested that Tat blocks the transcription of
MHC II genes. Since the constitutive expression (THP-1 Tat Blocks the Ability of B Cells to Present
a Superantigen to T Cellscells) and IFNg-inducible expression (HeLa cells) were
affected similarly, the most likely target of Tat was CIITA. A functional consequence of this squelching of CIITA
by Tat would be the loss of antigen processing andTo examine this notion directly, COS cells were cotrans-
fected with plasmid effectors coding for CIITA, Tat, and presenting function of the infected cell. A surrogate for
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this effect is the ability of the cell to present a superanti-
gen to T cells (reviewed by Herman et al., 1991). To
examine whether Tat could abrogate the superantigen
effect, we expressed CIITA alone or with Tat in RM3
cells, which are mutant Raji B cells that do not transcribe
MHC II genes due to defective CIITA genes (Calman and
Peterlin, 1988). Similar to the situation with IFNg, RM3
rather than Raji cells were chosen because of the slow
rate of decay of MHC II determinants on APC (Lanzavec-
chia et al., 1992; Nelson et al., 1994). Jurkat T cells, which
express the T cell antigen receptor, were transfected at
the same time with a plasmid target that contained sev-
eral NF-AT binding sites linked to the luciferase reporter
gene (NFAT-luc) (Fiering et al., 1990). When these B and
T cells were combined 2 days later, the staphylococcal
enterotoxin D (SED) was added to the culture. SED bridges
MCH II determinants and the T cell antigen receptor,
which results in T cell activation (reviewed by Herman
et al., 1991). The assay is diagrammed in Figure 2B (left
panel). In the presence of Tat, a 4-fold lower effect of
SED was observed with RM3 cells that coexpressed
CIITA and Tat at a ratio of 1:3 (Figure 2B, compare lanes
6 and 8). As determined by FACS, this reduction was
reflected in 3- to 4-fold lower levels of expression of
MHC II determinants on these cells (Figure 2B, DR and
DP, lanes 5±8). Thus, not only does Tat decrease levels
of expression of MHC II determinants by inhibiting the
Figure 4. CIITA Can Activate Transcription When Tethered Artifi-activity of CIITA, but it also attenuates the antigen pro-
cially to RNAcessing and presenting ability of the APC.
Full-length and N-terminal sequences in CIITA were linked to Rev
and tested for their ability to activate HIV-1 transcription via the
CIITA Binds to the Cyclin Box in the Cyclin T1 RRE. Rev, hybrid RevCDK9, and RevTat proteins were used as
Our squelching experiments suggested that CIITA also controls. The activity of the plasmid target (pRRESCAT) alone or
binds to the cyclin T1, which is the coactivator of Tat when coexpressed with Rev alone is given as one (white bars).
Coexpression of pRRESCAT with different plasmid effectors are(Wei et al., 1998). These interactions require the activa-
presented as follows: the hybrid RevCIITA, mutant RevCIITA(1±322),tion domain of Tat from positions 1 to 48; the cyclin box
and RevCIITA(323±1130) proteins, black bars; the hybrid RevCDK9of N-terminal 250 residues; a short C-terminal extension
protein, hatched bar; the hybrid RevTat protein, striped bar.
in the cyclin T1, which is called the Tat:TAR recognition Amounts of cotransfected plasmids are presented above the bar
motif or TRM; and the 59 bulge and central loop in TAR graph. Below the bar graph is presented a schematic of the experi-
(Bieniasz et al., 1998; Garber et al., 1998; Chen et al., ment. SLIIB refers to the high-affinity binding site for Rev on the
RRE. Although only one Rev is drawn, Rev is known to multimerize1999; Fujinaga et al., 1999; Ivanov et al., 1999). For Tat
on the SLIIB. Experiments are representative of three independentto block the activity of CIITA, the simplest scenario
transfections, which were performed in duplicate. Error bars givewould have CIITA interact with the same region in the
standard errors of the mean.
cyclin T1. To examine if CIITA binds to the cyclin T1,
we expressed full-length and deletion mutants of the
cyclin T1 as GST fusion proteins in E. coli and CIITA as
residues in the cyclin T1 (Figure 3A, lanes 5±8). Althougha 35S-labeled protein, which was transcribed and trans-
four fragments represent the central and C-terminal do-lated using the rabbit reticulocyte lysate. These proteins
mains of the cyclin T1, a contiguous fragment from posi-were then combined and the bound CIITA was isolated
tions 250 to 726 also did not bind to CIITA (data notusing glutathione-Sepharose beads. As presented in the
shown). Moreover, the input of informative GST chime-upper panel of Figure 3A, CIITA binds to the cyclin box
ras was similar (Figure 3A, lower panel). Thus, CIITA andin the cyclin T1, which contains two tandem repeats of
Tat bind to the cyclin box in the cyclin T1.five a helices (Figure 3A, lanes 2, 3, and 4) (Peng et al.,
Next, we wanted to map sequences in CIITA that are1998; Wei et al., 1998). Up to 5% of the input CIITA
responsible for this binding. Proteins were expressedwas recovered with the hybrid GST-cyclin T1 as well as
as above, except that deletion mutants of CIITA weremutant GST-cyclin T1(1±250) and GST-cyclin T1(1±322)
also created. As presented in Figure 3B, the cyclin T1proteins (Figure 3A, compare lanes 2, 3, and 4 with lane
bound to the N-terminal 322 residues in CIITA (Figure 3B,9). Similar to the binding of Tat to the cylin T1, the TRM
lanes 2 and 3). No binding was observed with sequencesdoes not appear to be essential for this binding (Figure
from positions 323 to 1130 (Figure 3B, lanes 4, 5, and3A, compare lanes 4 and 5). The main function of the
6), i.e., with central and C-terminal sequences in CIITA.TRM is in the formation of the tripartite complex between
We conclude that the N-terminal 322 residues in CIITATat, cyclin T1, and TAR (Bieniasz et al., 1998; Garber et
bind to the N-terminal 250 residues in the cyclin T1.al., 1998; Chen et al., 1999; Fujinaga et al., 1999; Ivanov
et al., 1999). CIITA did not bind to the C-terminal 400 Thus, CIITA binds specifically to the cyclin T1 in vitro.
Effects of Tat on MHC II Transcription
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Figure 6. Tat Competes for the Binding of CIITA to the Cyclin T In
Vitro
The hybrid GST-cyclin T1 protein was expressed in E. coli. CIITA
and Tat were transcribed and translated using the rabbit reticulocyte
lysate. CIITA and the hybrid GST-cyclin T1 protein were incubated
with a 10-fold excess of Tat. Whereas lanes 1±3 contain proteins in
the pull down, lanes 4 and 5 contain 25% of input proteins. Proteins
that were incubated together are given above the autoradiograph.
322 and C-terminal 808 residues to Rev [RevCIITA or
Figure 5. CIITA Interacts with the Cyclin T1 and Dominant-Negative mutant RevCIITA(1±322) and RevCIITA(323±1130) fusion
CDK9 Blocks the Activity of CIITA in Cells proteins]. These protein effectors and the pRRESCAT
(A) CIITA interacts with the cyclin T1 in cells. CIITA and the cyclin T1 target were coexpressed in COS cells. The assay is pre-
were coexpressed in COS cells. Anti-cyclin T1 immunoprecipitations
sented at the bottom of Figure 4. The hybrid RevCIITA andwere followed by Western blotting with antibodies against HA, which
mutant RevCIITA(1±322) proteins activated the HIV-1 LTRwas present on both CIITA and cyclin T1 (lanes 1±4). Five percent
via SLIIB to levels that were similar to those of the hybridof total lysates are also presented in lanes 5±8 (input). Coexpressed
proteins are given above the Western blot. Arrows point to CIITA RevCDK9 protein (Figure 4, compare lanes 3, 4, and 6).
and cyclin T1 bands. In sharp contrast, the hybrid mutant RevCIITA(323±1130)
(B) Dominant-negative CDK9 blocks the activation of the DRA pro- protein, which does not bind to the cyclin T1 (Figure 3B),
moter by CIITA in cells. CIITA and increasing amounts of the
did not activate pRRESCAT (Figure 4, lanes 5). TogetherDNCDK9 protein were coexpressed in COS cells. Coexpressed pro-
with the observation that the full-length CIITA had aboutteins are presented above the bar graph. Western blots of coex-
one-half the activity of the hybrid mutant CIITA(1±322)pressed proteins are below the bar graph. Bars represent the relative
activity from the DRA promoter by the following proteins: white bar, protein (Figure 4, compare lanes 3 and 4), these results
none; black bar, CIITA; striped bars, increasing amounts of the confirm our mapping data (Figure 3B) and suggest that
DNCDK9 protein. Experiments are representative of three indepen- a shorter chimera assumes a better conformation for
dent transfections, which were performed in duplicate. Error bars
the binding of the cyclin T1. The same situation appliesgive standard errors of the mean.
to the hybrid RevCDK9 protein, which also had one-
half the activity of the hybrid RevTat protein (Figure 4,
compare lanes 6 and 7). Importantly, the hybrid mutantN-Terminal Sequences in CIITA Can Also Activate
Transcription When Artificially Tethered to RNA RevCIITA(1±322) protein had the same activity as the
hybrid RevCDK9 protein (Figure 4, compare lanes 4 andOne functional consequence of this interaction would
be that sequences in CIITA that bind to the cyclin T1 6). Thus, CIITA not only binds to the cyclin T1 in vitro
but can also activate transcription via RNA in vivo.should activate transcription from the HIV-1 LTR via
RNA. In other words, CIITA rather than Tat should be
able to recruit P-TEFb. By modifying the viral promoter, CIITA Interacts with the Cyclin T1 and the Dominant-
Negative CDK9 Protein Blocks the Activityseveral heterologous RNA-tethering systems have been
created. For example, the high-affinity binding site (stem of CIITA in Cells
One prediction of the RNA tethering of CIITA is thatloop IIB, SLIIB) for the regulator of expression of virion
genes (Rev) has been grafted onto the stem of TAR CIITA binds to the cyclin T1 in vivo. To determine if CIITA
interacts with the cyclin T1 in cells, we coexpressed both(pRRESCAT) (Tiley et al., 1992). This plasmid target re-
sponds to fusion proteins between Rev and Tat, VP16 proteins in COS cells, immunoprecipitated the cyclin T1
with the anti-cyclin T1 antibody, and probed Western(Tiley et al., 1992), CDK8 (Gold and Rice, 1998), cyclin
T1 (Bieniasz et al., 1999), and CDK9 (Fujinaga et al., blots with the anti-HA antibody. Both proteins carried
the influenza haemagglutinin (HA) epitope tags (Wilson1998). Importantly, the kinase activity of CDK9 is re-
quired for the hybrid RevCDK9 protein to function (Fuji- et al., 1984). As presented in Figure 5A, the anti-cyclin T1
immunoprecipitations contained CIITA only when CIITAnaga et al., 1998). This finding suggests that the phos-
phorylation of the CTD occurs via RNA in this system. was coexpressed with the cyclin T1 (Figure 5A, compare
lanes 3 and 4). Thus, CIITA binds to the cyclin T1 in vitroTo determine whether CIITA can activate transcription
via RNA, we linked the full-length CIITA or its N-terminal and in vivo.
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Figure 7. A Model for the Inhibition of CTIIA
by Tat for the Binding to P-TEFb
(A) In uninfected cells, RFX and NFY com-
plexes (RFX::NFY) recruit CIITA to MHC II pro-
moters (step 1). Together with other interact-
ing proteins, P-TEFb activates the expression
of MHC II genes. P-TEFb phosphorylates the
C-terminal domain of RNAP II (step 2), leading
to efficient elongation of transcription (step 3).
(B) In cells that are infected by HIV-1, Tat is
synthesized. Since Tat and CIITA bind to the
same surface in the cyclin T1, Tat blocks the
ability of CIITA to activate the transcription
of MHC II genes (step 4). Antigen processing
and presentation are impaired. The interac-
tion between Tat, cyclin T1, and TAR in-
creases rates of elongation of HIV-1 tran-
scription (step 5).
The second prediction is that CIITA binds to the cyclin of Tat (Figure 6, lane 3). As presented in the autoradio-
graph, Tat competes efficiently for the binding of CIITAT1 to recruit CDK9 to MHC II promoters and thus acti-
vates their transcription. In this scenario, CIITA inter- to the cyclin T1 (Figure 6, compare lanes 2 and 3). Thus,
the squelching observed in vivo was proved in vitro,acts with P-TEFb. To this end, we used a mutant CDK9
protein (DNCDK9) that contains a substitution of the where Tat blocked the binding of CIITA to the cyclin T1.
aspartate at position 167 to asparagine, which abol-
ishes its kinase activity and blocks Tat transactivation
Discussion(Mancebo et al., 1997). It should also block the ability
of CIITA to function on MHC II promoters. CIITA and
In this study, we confirmed that the infection by HIV-1increasing amounts of the DNCDK9 protein were coex-
blocks the expression of MHC II determinants in cells.pressed in COS cells. As presented in Figure 5B, the
This transcriptional block was found to be due to Tat,DNCDK9 protein decreased the expression from the
which inhibited the activity of CIITA by binding to theDRA promoter up to 10-fold in a dose-dependent fash-
same surface of the cyclin T1. N-terminal sequences inion (Figure 5B, compare lanes 3, 4, and 5 with lane
CIITA bound to the cyclin box in the cyclin T1, and this2). Importantly, the DNCDK9 protein did not affect the
interaction could be documented in vitro, in vivo, andexpression of CIITA from CMV or SV40 promoters (Fig-
in functional studies. Tat also blocked the ability of Bure 5B, upper Western blot; data not shown). It also did
cells to present a superantigen to T cells. Not only didnot affect the basal activity of the DRA promoter (data
the DNCDK9 protein block the activity of CIITA, but Tatnot shown). The lack of inhibition of the CMV promoter
interfered with the binding of CIITA to the cyclin T1 inby the DNCDK9 protein confirms a previous report
vitro. Thus, CIITA requires P-TEFb to activate transcrip-(Mancebo et al., 1997) and suggests that only a subset
tion of its target genes. Moreover, by blocking the ex-of promoters is regulated by P-TEFb. Moreover, the de-
pression of genes required for antigen processing andcreased activity of CIITA correlated with increasing
presentation, Tat could potentiate the immunodefi-amounts of the DNCDK9 protein (Figure 5B, lower West-
ciency that ultimately results in AIDS.ern blot). We conclude that not only can CIITA function
Tat acted at the level of MHC II transcription. Thiswhen tethered artificially to RNA and bind to the cyclin
observation confirms a previous study in which MHC IIT1 in vitro and in vivo, but that P-TEFb is also required
but not MHC I transcripts were absent in virally infectedfor its activity in the transcription of MHC II genes.
macrophage hybridomas (Polyak et al., 1997). In these
cells, antigen processing and presentation was severely
impaired. Moreover, the same phenotype was describedTat Competes for the Binding of CIITA
to the Cyclin T1 in primary macrophages (Polyak et al., 1997). Our studies
found a smaller effect on levels of MHC I determinantsTo this point, all data indicated that Tat inhibits CIITA
directly by blocking its binding to the cyclin T1. RNA- on these cells. This decreased expression of MHC I
determinants results from a combination of their tran-tethering experiments also suggested that Tat binds to
the cyclin T1 with a greater affinity than does CIITA. To scriptional blockade by Tat (Howcroft et al., 1993; Brown
et al., 1998) and intracytoplasmic sequestration by theexamine if Tat competes for the binding of CIITA to the
cyclin T1, binding competition studies were performed viral Nef protein (Greenberg et al., 1998; Le Gall et al.,
1998). Rather, our study focused on the selective block-in vitro (Figure 6). All proteins were made as described
earlier. Constant amounts of the hybrid GST-cyclin T1 ade of antigen processing and presentation of MHC II
compartments, which could contribute to the observedprotein and CIITA were incubated with a 10-fold excess
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inadequate humoral and T helper cell responses in the 7). MHC II transcription occurs in a series of well-orches-
trated steps, which end with the modification of RNAPIIinfection by HIV-1 (reviewed by Miedema, 1992; McMi-
chael, 1998; Rosenberg et al., 1999). Thus, by blocking by P-TEFb. The CTD is phosphorylated and RNAPIIo
elongates on MHC II genes. When these cells are in-the function of CIITA, HIV-1 creates a picture that resem-
bles BLS in the infected cell! This finding is reminiscent fected by HIV-1, Tat is synthesized. Tat binds to the
same region in the cyclin T1. This interaction blocks theof the infection by cytomegalovirus (CMV), which also
blocks the transcription of MHC II genes (Sedmak et al., activity of CIITA and the transcription of MHC II, Ii, DMA,
and DMB genes. By competing for its binding to the1994). However, CMV targets Janus kinases, so that the
administration of IFNg does not induce the expression cyclin T1, Tat inhibits the function of CIITA. Future exper-
iments will reveal additional structural and functionalof CIITA (Miller et al., 1998).
Macrophages are professional APC (reviewed by Un- aspects of this model, in particular if mutations in the
cyclin T1 could differentiate between Tat and CIITA. Aanue, 1984). By infecting them, HIV-1 targets the very
cell that represents the first line of defense against this mutant cyclin T1 could then be constructed that no
longer supports the binding of Tat but still carries outmicroorganism. Not only does it target the constitutive
expression of MHC II determinants, but it also blocks normal cellular functions, i.e., supports the transcription
of MHC II genes. These cells should suppress viral repli-their induction by IFNg. Thus, infected cells have a di-
minished capacity to process and present foreign anti- cation but process and present foreign antigens opti-
mally, which would lead to a more vigorous immunegenic determinants. Together with impaired chemo-
taxis, cytokine production, and expression of other response against HIV-1. Interestingly, such a polymor-
phism in the cyclin T1 might already exist. Highly ex-receptors (reviewed by Knight et al., 1990 and Petit et al.,
1988; Ennen et al., 1990; Roilides et al., 1990; Macatonia posed sexual workers in East Africa exhibit vigorous
antiviral immune responses but no infection by HIV-1et al., 1992; Polyak et al., 1997), HIV-1 sets up protected
microenvironments, where it replicates (Hockett et al., (Rowland-Jones et al., 1999). In other words, they might
mimic the species-specific restriction to Tat transactiva-1999). That viruses still contain MHC I and MHC II deter-
minants on their surface (Gelderblom et al., 1987) is a tion, where the change of one residue in the cyclin T1
prevents the binding of Tat to TAR (Bieniasz et al., 1998;testament of the slow rate of decay of these antigens
on some APC (Lanzavecchia et al., 1992; Nelson et al., Garber et al., 1998; Chen et al., 1999; Fujinaga et al.,
1999; Kwak et al., 1999).1994), possibly on dendritic cells (reviewed by Knight
et al., 1990; Meltzer and Gendelman, 1992). However,
Experimental Proceduressince the synthesis of Ii, DMA, and DMA proteins is also
blocked by Tat, the loading of MHC II determinants with
Plasmid Constructionnew peptides should be severely compromised despite
Plasmids coding for Tat (pCMVTat), TatC30G (pCMVTatC30G), the
their persistence on the cell surface (Lanzavecchia et DRA promoter linked to CAT (pDRASCAT), CIITA (pSVCIITA or
al., 1992; Nelson et al., 1994). Thus, HIV-1 joins a long pCMVCIITA), the HIV-1 LTR linked to CAT (pHIVSCAT), the HIV-1
LTR where TAR was replaced by SLIIB from the RRE linked to thelist of pathogens that can subvert the immune system
CAT (pRRESCAT), REVTat (pREVTat), REVCDK9 (pREVCDK9), cyclinto its own use and block as vigorous an immune re-
T1 (pCMVcyclin T1), DNCDK9 (pCMVCDK9D167N), and the glutathi-sponse as would be required to eradicate the infection.
one S-transferase (GST)-fusion proteins of full-length cyclin T1 andIn terms of CIITA, it requires P-TEFb for its effects.
deletion mutants of the cyclin T1 have been described previously
Although the binding of CIITA to DNA-bound activators (Tiley et al., 1992; Mancebo et al., 1997; Fontes et al., 1999; Fujinaga
has not been demonstrated, CIITA is not an RNA-binding et al., 1999). CIITA and all deletion mutants of CIITA, these from
positions 1 to 322, 323 to 507, 508 to 747, and 748 to 1130 wereprotein. Thus, RNA tethering is not a requirement for
made by PCR and subcloned into EcoRI and XhoI sites of pcDNA3.the modification of RNAPII and for efficient elongation
To construct pREVCIITA, pREVCIITA(1±322), and pREVCIITA(323±of transcription. How does CIITA play its transcriptional
1130), CIITA and fragments of CIITA from positions 1 to 322 androles? Its recruitment occurs via the RFX and nuclear
323 to 1130 were amplified by PCR and subcloned into HindIII and
factor Y (NFY) complexes, both of which bind to the SalI sites of pcREV. All constructs were confirmed by DNA se-
conserved upstream sequences in MHC II promoters quencing.
(reviewed by Mach et al., 1996). Then, CIITA acts as a
Cell Culturetranscriptional integrator. It binds to GTFs (Fontes et al.,
COS, HeLa, and 293T cells were cultured in Dullbecco's modified1997; Mahanta et al., 1997), Bob1 (Fontes et al., 1996),
Eagle's medium with 10% fetal calf serum and antibiotics. THP-1,and CBP (Kretsovali et al., 1998; Fontes et al., 1999). RM3 plus Jurkat cells were cultured in RPMI-1640 with 10% fetal
Whereas the former proteins attract RNAPII and specify calf serum and antibiotics. All cells were grown at 378C with 5% CO2.
the site of initiation of transcription, CBP, which is a
Infection by HIV-1histone acetyltransferase, increases rates of reinitiation
HIV-1YU2 proviral DNA (1 mg) was transfected in 293T cells. Forty-from chromatinized DNA templates (Sheridan et al.,
eight hours after the transfection, supernatants were harvested and1997). The final actor is P-TEFb, which then modifies
filtered, and then THP-1 cells were cultured in these supernatants
RNAPII to clear the promoter and elongate on MHC II for 8 days. Cells were harvested and stained with anti-HLA-DR, anti-
genes. Most likely, other parts of CIITA and RNAPII act HLA-DP, or anti-HLA-A, -B, and -C (G46±2.6) antibodies, which were
conjugated to FITC (Becton Dickinson) and analyzed by FACS. Virusin concert, so that RNAPII is held near CIITA and P-TEFb
production of both supernatants from 293T and THP-1 cells werefor CDK9 to phosphorylate the CTD and possibly other
quantified by p24Gag ELISA (NEN Life Science Products).targets. This observation explains the ability of the
DNCDK9 protein to block the transcription of MHC II Induction by IFNg
genes. To establish stable transformants, pcDNA3Tat or empty plasmid
vector were transfected to HeLa cells by lipofectamine (GIBCO±The following model emerges from this study (Figure
Immunity
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BRL). The cells were selected by 500 mg/ml of G418 for 2 weeks. from a patient at risk for acquired immune deficiency syndrome
(AIDS). Science 220, 868±871.Transformants (4 3 104 cells) were treated with 1000 U/ml of human
IFNg (Boehringer Mannheim) for 72 hr. The expression of Tat was Bieniasz, P.D., Grdina, T.A., Bogerd, H.P., and Cullen, B.R. (1998).
confirmed by Western blotting and CAT assays with the pHIVSCAT. Recruitment of a protein complex containing Tat and cyclin T1 to
Harvested cells were stained and analyzed by FACS as above. TAR governs the species specificity of HIV-1 Tat. EMBO J. 17, 7056±
7065.
CAT Assay Bieniasz, P.D., Grdina, T.A., Bogerd, H.P., and Cullen, B.R. (1999).
COS cells were transfected with different combinations of plasmid Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal
effectors and targets using lipofectamine (GIBCO±BRL). Twenty- repeat promoter proximal RNA target is both necessary and suffi-
four hours after the transfection, COS cells were washed with phos- cient for full activation of transcription. Proc. Natl. Acad. Sci. USA
phate-buffered saline and lysed in a lysis buffer containing 0.25 M 96, 7791±7796.
Tris±HCl (pH 7.5) and 0.1% Triton X-100. Chloramphenicol acetyl-
Brown, J.A., Howcroft, T.K., and Singer, D.S. (1998). HIV Tat protein
transferase (CAT) assays and Western blotting were performed as
requirements for transactivation and repression of transcription are
described previously (Fontes et al., 1999).
separable. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17,
9±16.
GST Pull-Down and Binding Competition Assays
Calman, A.F., and Peterlin, B.M. (1988). Evidence for a trans-actingGST-cyclin T1 fusion proteins were produced and purified as de-
factor that regulates the transcription of class II major histocompati-scribed (Fujinaga et al., 1999). Two micrograms of each chimera
bility complex genes: genetic and functional analysis. Proc. Natl.were incubated with 35S-labeled CIITA, its derivatives, and Tat (in
Acad. Sci. USA 85, 8830±8834.binding competition assays), which were transcribed and translated
Chang, C.H., Fontes, J.D., Peterlin, M., and Flavell, R.A. (1994). Classusing the rabbit reticulocyte lysate (TNT system [Promega]). Each
II transactivator (CIITA) is sufficient for the inducible expression ofbinding reaction was perfomed in 100 ml of buffer (20 mM HEPES [pH
major histocompatibility complex class II genes. J. Exp. Med. 180,7.9], 0.5% Nonidet P-40, 1% Triton X-100, 0.7% b-mercaptoethanol,
1367±1374.0.2% BSA, 150 mM KCl) for 3 hr at 48C. After the binding, glutathione
Chen, D., Fong, Y., and Zhou, Q. (1999). Specific interaction of TatSepharose beads were added and washed with the same buffer
with the human but not rodent P-TEFb complex mediates the spe-without BSA three times. Bound proteins (pull down) and in vitro
cies-specific Tat activation of HIV-1 transcription. Proc. Natl. Acad.translated proteins (input) were separated on 15% SDS-PAGE and
Sci. USA 96, 2728±2733.analyzed by autoradiography.
Douhan, J., 3rd, Hauber, I., Eibl, M.M., and Glimcher, L.H. (1996).
Immunoprecipitation Genetic evidence for a new type of major histocompatibility complex
pCMVCIITA, pCMVcyclin T1, or the empty plasmid vector (2 mg each) class II combined immunodeficiency characterized by a dyscoordi-
were cotransfected into COS cells as above. Cells were harvested in nate regulation of HLA-D a and b chains. J. Exp. Med. 183, 1063±
buffer A containing 150 mM KCl, 50 mM Tris (pH 7.5), 5 mM EDTA, 1069.
0.1% Triton X-100, 5 mM DTT, 10 mg/ml aprotinin, and 1 mg/ml Ennen, J., Seipp, I., Norley, S.G., and Kurth, R. (1990). Decreased
leupeptin. Cell lysates were incubated with 4 ml of anti-cyclin T1 accessory cell function of macrophages after infection with human
antibody (Peng et al., 1998), which was a gift from David H. Price immunodeficiency virus type 1 in vitro. Eur. J. Immunol. 20, 2451±
(University of Iowa) for 2 hr at 48C. Samples were mixed with 20 2456.
ml of protein G±conjugated agarose beads for another hour, and Fiering, S., Northrop, J.P., Nolan, G.P., Mattila, P.S., Crabtree, G.R.,
immunoprecipitations were washed with buffer A four times. West- and Herzenberg, L.A. (1990). Single cell assay of a transcription
ern blotting was performed with anti-HA antibodies as above. factor reveals a threshold in transcription activated by signals ema-
nating from the T-cell antigen receptor. Genes Dev. 4, 1823±1834.
Superantigen Assay
Fontes, J.D., Jabrane-Ferrat, N., Toth, C.R., and Peterlin, B.M.
pCMVCIITA (10 mg) was cotransfected with pCMVTat or the empty
(1996). Binding and cooperative interactions between two B cell-
plasmid vector (30 mg) into 107 RM3 cells by electroporation (300
specific transcriptional coactivators. J. Exp. Med. 183, 2517±2521.
V, 975 mF) 48 hr prior to coculture. The NFAT-luciferase reporter
Fontes, J.D., Jiang, B., and Peterlin, B.M. (1997). The class II trans-gene (40 mg) was transfected in 107 Jurkat cells by electroporation
activator CIITA interacts with the TBP-associated factor TAFII32.24 hr before coculture. Transfected or untransfected RM3 cells (105
Nucleic Acids Res. 25, 2522±2528.cells each) were cocultured with transfected Jurkat cells (105 cells
Fontes, J.D., Kanazawa, S., Jean, D., and Peterlin, B.M. (1999). Inter-each) in 90 ml of medium with or without 300 mg/ml of SED (Toxin
actions between the class II transactivator and CREB binding pro-Technology) for 16 hr. Cells were lysed and luciferase assays were
tein increase transcription of major histocompatibility complex classperformed as described previously (Fiering et al., 1990). The expres-
II genes. Mol. Cell. Biol. 19, 941±947.sion of MHC II determinants was analyzed with anti-HLA-DR or
Fujinaga, K., Cujec, T.P., Peng, J., Garriga, J., Price, D.H., Grana,-DP antibodies by FACS.
X., and Peterlin, B.M. (1998). The ability of positive transcription
elongation factor B to transactivate human immunodeficiency virusAcknowledgments
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